Completed PHASE2 INTERVENTIONAL 2-arm NCT01088529

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone

Sponsor: Cougar Biotechnology, Inc.

Interventions Abiraterone Acetate LHRHa Prednisone

Updated 6 times since 2017 Last updated: May 1, 2014 Started: Dec 31, 2009 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prostate Cancer and is currently completed. Cougar Biotechnology, Inc. leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cougar Biotechnology, Inc.

Data source: Cougar Biotechnology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States